BCL2L1_pLX307 Citations (1)
Originally described in: Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in beta-Catenin-Active Cancers.Rosenbluh J, Mercer J, Shrestha Y, Oliver R, Tamayo P, Doench JG, Tirosh I, Piccioni F, Hartenian E, Horn H, Fagbami L, Root DE, Jaffe J, Lage K, Boehm JS, Hahn WC Cell Syst. 2016 Sep 28;3(3):302-316.e4. doi: 10.1016/j.cels.2016.09.001. PubMed Journal
Articles Citing BCL2L1_pLX307
Articles |
---|
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. Nardi F, Perurena N, Schade AE, Li ZH, Ngo K, Ivanova EV, Saldanha A, Li C, Gokhale PC, Hata AN, Barbie DA, Paweletz CP, Janne PA, Cichowski K. J Clin Invest. 2023 Aug 15;133(16):e167651. doi: 10.1172/JCI167651. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.